Reversal effect of ouabain on multidrug resistance in esophageal carcinoma EC109/CDDP cells by inhibiting the translocation of Wnt/β-catenin into the nucleus
The incidence of esophageal carcinoma is increasing throughout the world. A major obstacle to its treatment is acquired multidrug resistance (MDR) which results in the failure of chemotherapy and patient relapse. Here, we identified that ouabain is capable of reversing MDR to cisplatin (CDDP) in EC109/CDDP cells and explore the possible mechanisms of action. The parental and the MDR cell lines were both sensitive to ouabain with 50 % inhibitory concentration (IC50) values of 258.11 and 710.63 nM, respectively. Cisplatin cytotoxicity increased in the EC109/CDDP cells by the addition of ouabain which helps promote CDDP-induced apoptosis. Ouabain at 20 nM effectively reduced the IC50 of CDDP in EC109/CDDP cells from 36.54 to 3.39 μM. This represents a 10.78-fold increase in sensitization to CDDP. We also found that ouabain was capable of down regulating the expression of P-glycoprotein (P-gp) and Bcl-2 in a dose- and time-dependent manner. Finally, the results indicated that ouabain suppressed Wnt luciferase report (TOPFlash) activity obviously in EC109/CDDP and depressed the translocation of β-catenin into the nucleus. Moreover, ouabain showed reversal effect of MDR to CDDP in nude mouse xenograft model, and reduced the protein level of β-catenin (Y333) in tumor tissue of CDDP plus ouabain group. All data proved that ouabain has a potent β-catenin-dependent anti-MDR effect.
KeywordsOuabain Multidrug resistance Esophageal carcinoma Wnt/β-catenin
The study was supported by Jiangsu Provincial Special Program of Clinical Medical Science (BL2014040), Suzhou Science and Technology Development Program (SZS201509), and Natural Science Foundation of the Jiangsu Higher Education Institutions of China (11KJB180010).
Compliance with ethical standards
All animal studies were carried out in compliance with the Guide for the Care and Use of Laboratory Animals of Nantong University, China.
Conflict of interest
- 8.Zandvliet M, Teske E, Schrickx JA. Multi-drug resistance in a canine lymphoid cell line due to increased p-glycoprotein expression, a potential model for drug-resistant canine lymphoma. Toxicology In Vitro: an International Journal Published in Association with BIBRA. 2014;28:1498–506.CrossRefGoogle Scholar
- 11.Nakanishi Y, Ochiai A, Akimoto S, Kato H, Watanabe H, Tachimori Y, Yamamoto S, Hirohashi S. Expression of e-cadherin, alpha-catenin, beta-catenin and plakoglobin in esophageal carcinomas and its prognostic significance: Immunohistochemical analysis of 96 lesions. Oncology. 1997;54:158–65.CrossRefPubMedGoogle Scholar
- 18.Di Pietro A, Conseil G, Perez-Victoria JM, Dayan G, Baubichon-Cortay H, Trompier D, Steinfels E, Jault JM, de Wet H, Maitrejean M, Comte G, Boumendjel A, Mariotte AM, Dumontet C, McIntosh DB, Goffeau A, Castanys S, Gamarro F, Barron D. Modulation by flavonoids of cell multidrug resistance mediated by p-glycoprotein and related abc transporters. Cellular and Molecular Life Sciences: CMLS. 2002;59:307–22.CrossRefPubMedGoogle Scholar
- 20.Kelly RJ, Draper D, Chen CC, Robey RW, Figg WD, Piekarz RL, Chen X, Gardner ER, Balis FM, Venkatesan AM, Steinberg SM, Fojo T, Bates SE. A pharmacodynamic study of docetaxel in combination with the p-glycoprotein antagonist tariquidar (xr9576) in patients with lung, ovarian, and cervical cancer. Clinical Cancer Research: an Official Journal of the American Association for Cancer Research. 2011;17:569–80.CrossRefGoogle Scholar
- 21.Kuppens IE, Witteveen EO, Jewell RC, Radema SA, Paul EM, Mangum SG, Beijnen JH, Voest EE, Schellens JH. A phase i, randomized, open-label, parallel-cohort, dose-finding study of elacridar (gf120918) and oral topotecan in cancer patients. Clinical Cancer Research: an Official Journal of the American Association for Cancer Research. 2007;13:3276–85.CrossRefGoogle Scholar
- 22.Morschhauser F, Zinzani PL, Burgess M, Sloots L, Bouafia F, Dumontet C. Phase i/ii trial of a P-glycoprotein inhibitor, Zosuquidar.3HCl trihydrochloride (ly335979), given orally in combination with the CHOP regimen in patients with non-Hodgkin’s lymphoma. Leukemia & Lymphoma. 2007;48:708–15.CrossRefGoogle Scholar
- 24.Kulikov A, Eva A, Kirch U, Boldyrev A, Scheiner-Bobis G. Ouabain activates signaling pathways associated with cell death in human neuroblastoma. Biochim Biophys Acta. 1768;2007:1691–702.Google Scholar
- 27.Lin CF, Wan SW, Chen MC, Lin SC, Cheng CC, Chiu SC, Hsiao YL, Lei HY, Liu HS, Yeh TM, Lin YS. Liver injury caused by antibodies against dengue virus nonstructural protein 1 in a murine model. Laboratory Investigation; a Kournal of Technical Methods and Pathology. 2008;88:1079–89.CrossRefGoogle Scholar
- 35.Rosano L, Cianfrocca R, Spinella F, Di Castro V, Nicotra MR, Lucidi A, Ferrandina G, Natali PG, Bagnato A. Acquisition of chemoresistance and emt phenotype is linked with activation of the endothelin a receptor pathway in ovarian carcinoma cells. Clinical Cancer Research: an Official Journal of the American Association for Cancer Research. 2011;17:2350–60.CrossRefGoogle Scholar